GERMANY: AudioCure Pharma wins the Berlin Brandenburg Innovation Award 2024 with its new active ingredient AC102

Christin Galetzka and Dr. Alena Meis from AudioCure accept the innovation award. Source: Stefan Schubert | Agentur Medienlabor

Award-winning active ingredient AC102 was able to almost completely restore hearing in the noise trauma model. Clinical study with sudden hearing loss patients is underway.

It is our goal to be able to offer patients with sudden hearing loss a more effective therapy in the future.”

— Prof. Hans Rommelspacher

BERLIN, GERMANY, January 2, 2025 / EINPresswire.com / -- AudioCure Pharma GmbH from Berlin wins the Berlin Brandenburg Innovation Prize 2024 with its novel active ingredient AC102. If approved as a drug, AC102 could represent an important step forward in the treatment of sudden hearing loss, for which there are currently no approved

and proven effective treatment options.

A major problem with sudden hearing loss is that it can lead to massive damage to the auditory sensory cells and their connection to the auditory nerve in the inner ear. AudioCure's new active ingredient AC102 counteracts this in a variety of ways in the laboratory model. It has been shown that AC102 penetrates deep into the inner ear and also reaches areas in the inner ear that are essential for the perception of low frequencies and speech. In addition, AC102 also shows significant effects in other hearing loss models such as tinnitus. "The Berlin Brandenburg Innovation Award 2024 recognizes the commitment of the entire AudioCure team to turn an idea into a clinical project," emphasizes AudioCure Managing Director Dr. Reimar Schlingensiepen. "It is our goal to be able to offer patients with sudden hearing loss a more effective therapy in the future," says Prof. Hans Rommelspacher, founder of AudioCure Pharma GmbH.

AC102 is currently being tested for its effectiveness in a Europe-wide clinical study on patients with sudden hearing loss.

About AudioCure:
AudioCure is an innovative pharmaceutical company in the clinical phase based in Berlin, Germany. AudioCure has developed a unique portfolio of small molecular active ingredients that protect and restore the structures of the inner ear affected by hearing impairment. After the safety and tolerability of the lead substance AC102 was demonstrated in a Phase 1 study on healthy volunteers, the substance is currently being investigated in a Phase 2 clinical study on patients with idiopathic sudden hearing loss. Projects to treat tinnitus and to support residual hearing in cochlear implant wearers are also in development.

About the Innovation Award:
With the Innovation Award, the two states of Berlin and Brandenburg annually recognize innovative and outstanding entrepreneurial work. With the involvement of commercial companies and other institutions as private partners, the award is also a prize from business for business. Since it was first awarded in 1984 in West Berlin (since 1992 together with Brandenburg), more than 180 winners have been honored from over 4,560 applications. The award ceremony with the announcement of the winners took place on November 29, 2024.